緩釋注射劑：技術、療法、市場、預測

Extended-Release Injectable Drugs: Technology, Therapeutics, Markets, & Forecasts

出版日期: 2023年06月12日 | 出版商:

Greystone Research Associates | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

本報告研究了緩釋注射藥物市場，並提供了市場概況，包括需求趨勢、市場促進因素、藥物概述以及進入市場的公司概況。

內容

執行摘要
注塑市場動態
傾向於自我管理
注射製劑技術
注射裝置設計的創新
治療需求的驅動因素
市場因素
患者的依從性和可用性
醫療法規
管理式醫療倡議
競爭格局
風險因素
緩釋製劑技術
可生物降解聚合物
聚乙二醇
解放軍/人民解放軍
聚醚酯
緩釋製劑平台
BEPO(MedinCell)
ChroniJect (Oakwood Laboratories/PharmaSophia)
CriticalMix (Critical Pharmaceuticals)
Depofoam (Pacira)
FluidCrystal (Camarus)
LinkeRx (Alkermes)
Medisorb (Alkermes)
Medusa (Recipharm/Avadel)
Nanocrystals (Alkermes)
Optisomes (Talon/Spectrum)
PolyActive (Octoplus)
Q-Sphera (Midatech Pharma)
SABER/SAIB (DURECT)
SynBiosys (Innocore)
TransCon (Ascendis)
物理過程控制方法
超臨界流體
SCF for Nanoparticle Formulations
Formulplex（超臨界溶液）
Ferro
SCF extraction of emulsions (SFEE)
緩釋注射劑 - 發育因子
組合元素
穩定
控制因素
緩釋注射劑 - 產品分析
阿立□唑
月桂□阿立□唑
布比卡因
丁丙諾啡
阿糖胞甘
阿糖胞甘和柔紅黴素
阿黴素
雌二醇
艾塞那□
氟奮乃靜癸酸酯
醋酸戈捨瑞林
格拉司瓊
干擾素
伊立替康
醋酸蘭瑞□
亮丙瑞林
亮丙瑞林長效製劑
甲羥孕酮
納曲酮
醋酸奧曲□
奧氮平雙羥□酸鹽
帕潘立酮棕櫚酸酯
帕瑞□
Pegvariase-pqpz
利培酮
睪酮
曲普瑞林
曲安奈德
硫酸長春新鹼
血糖控制
AB101（Rezolute）
激素缺乏
人類生長激素/Ascendis
成癮
CAM2038（Camurus）
疼痛管理
Posidur/Durect
心臟病學
曲前列環素/Ascendis Pharma
神經病學
Lerday/Risperidone(DURECT/Zogenix)
腫瘤學
CAM2032（Camurus）
緩釋注射劑 - 特定區域分析
成癮
血糖控制
感染
肝炎
神經病學
精神分裂症
雙相情感障礙
腫瘤學
疼痛管理
生殖醫學
生育能力
子宮內膜異位症
與更年期相關的血管舒縮症狀
公司簡介
Alkermes
Amylin
AntriaBio
Ascendis Pharma
AstraZeneca
Aurobundo
Avadel
Biomarin
Camurus
Critical Pharmaceuticals
DURECT
Eli Lilly
Enzon
Ipsen
Janssen
NanOlogy
Novartis
OctoPlus
Oakwood Laboratories/PharmaSophia
Pacira
PhaseBio Pharmaceuticals
Recipharm AB
Roche
Sanofi
Taiwan Liposome Company (TLC)
Xbrane Bipharma

簡介目錄

This new market study, “Extended-Release Injectable Drugs: Technology, Therapeutics, Markets and Forecasts ” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for injectable drug products engineered for controlled release. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Engineered Injectables that Address Chronic Conditions

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to produce APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.

What You Will Learn:

What are the marketed Extended-Release injectable drug products, what Extended-Release formulation technologies are used, and who markets them?

What are the major factors driving Extended-Release injectable drug demand?

What Extended-Release injectable drug candidates are in late-stage clinical development and what is their potential impact?

How important are drug developer-formulation technologist relationships in the Extended-Release market segment, and what are the key alliances in the industry?

What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for Extended-Release injectable drug products?